BMS-663513
Phase 1Small molecule
Bristol-Myers SquibbBMS-663513 is one of 16 small molecule programs targeting Small Cell Lung Carcinoma. It is currently in Phase 1.
1
Indications
3
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Small Cell Lung Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Adriamycin
PfizerPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Vepesid
AAvyxa
Phase 2
Paraplatin
AAvyxa
Phase 2
LY2510924
Eli LillyPhase 2
NGR-Htnf
AAGC Biologics S.p.A.
Phase 2
Glufosfamide
TThreshold Pharmaceuticals
Phase 2
Bemiparin
RRovi Pharmaceuticals Laboratories
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Advanced Solid Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BMS-663513. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company